

News Article downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009  
Read [FDA Approves SAMSCA\(TM\) \(tolvaptan\), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia](http://www.bioportfolio.com/news/FDA_Approves_SAMSCA(TM)__(tolvaptan),_the_First.html) on BioPortfolio.com  
([http://www.bioportfolio.com/news/FDA\\_Approves\\_SAMSCA\(TM\)\\_\\_\(tolvaptan\),\\_the\\_First.html](http://www.bioportfolio.com/news/FDA_Approves_SAMSCA(TM)__(tolvaptan),_the_First.html))

## **FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia**

**Thursday 21st of May 2009 13:51**

BioPortfolio no longer holds the full text of this article in PDF form.

**[Click Here To Read BioPortfolio's Web Page on FDA Approves SAMSCA\(TM\) \(tolvaptan\), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia](#)**

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)  
Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:  
Peter Barfoot Managing Director, BioPortfolio Ltd.  
UK Tel: (+44) 1300 321501  
USA Voicemail and Fax: (+1) 415 680 2472  
[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.  
BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10  
Copyright 1997-2009 - BioPortfolio Limited.



